CN104208670B - A kind of pharmaceutical composition for treating hepatitis B - Google Patents
A kind of pharmaceutical composition for treating hepatitis B Download PDFInfo
- Publication number
- CN104208670B CN104208670B CN201410453195.5A CN201410453195A CN104208670B CN 104208670 B CN104208670 B CN 104208670B CN 201410453195 A CN201410453195 A CN 201410453195A CN 104208670 B CN104208670 B CN 104208670B
- Authority
- CN
- China
- Prior art keywords
- haptens
- hepatitis
- vaccine
- stage
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 62
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims abstract description 56
- 229940124736 hepatitis-B vaccine Drugs 0.000 claims abstract description 56
- 229940079593 drug Drugs 0.000 claims abstract description 51
- 230000002265 prevention Effects 0.000 claims abstract description 36
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 19
- 238000002483 medication Methods 0.000 claims abstract description 8
- 230000021615 conjugation Effects 0.000 claims abstract description 4
- 230000004936 stimulating effect Effects 0.000 claims abstract description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 9
- HCOLPNRPCMFHOH-UHFFFAOYSA-N Prodigiosin Natural products CCCCCC1C=C(C=C/2N=C(C=C2OC)c3ccc[nH]3)N=C1C HCOLPNRPCMFHOH-UHFFFAOYSA-N 0.000 claims description 9
- 208000037386 Typhoid Diseases 0.000 claims description 9
- TWFGRJUTAULJPZ-USZBIXTISA-N prodigiosin Chemical compound N1=C(C)C(CCCCC)=C\C1=C/C1=NC(C=2[N]C=CC=2)=C[C]1OC TWFGRJUTAULJPZ-USZBIXTISA-N 0.000 claims description 9
- 201000008297 typhoid fever Diseases 0.000 claims description 9
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 8
- 239000002158 endotoxin Substances 0.000 claims description 7
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- 125000000468 ketone group Chemical group 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- -1 polysaccharide nucleic acid Chemical class 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 230000021523 carboxylation Effects 0.000 claims description 3
- 238000006473 carboxylation reaction Methods 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 150000004676 glycans Polymers 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 230000005923 long-lasting effect Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000010255 intramuscular injection Methods 0.000 description 10
- 239000007927 intramuscular injection Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229960002143 fluorescein Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A kind of pharmaceutical composition for treating hepatitis B, including, first stage medication, second stage medication and phase III medication ... N stage medications, wherein, first stage medication is：Prevention hepatitis B vaccine, haptens A and auxiliary agent；Second stage medication is prevention hepatitis B vaccine, haptens B and auxiliary agent；Phase III medication is prevention hepatitis B vaccine, haptens C and auxiliary agent, ... N stage medications are anti-use hepatitis B vaccine, haptens N and auxiliary agent, make the prevention hepatitis B vaccine in each stage from stimulating body persistently to produce antibody after corresponding different hapten conjugations.The present invention is connected using different haptens with prevention with hepatitis B vaccine, enable the antibody that produces in patient's short time long lasting for, so as to reach the purpose for thoroughly curing hepatitis B, the pharmaceutical composition convenient sources of the present invention, therapeutic effect is notable, and therapeutic process is easily operated, it is that can thoroughly cure the initiative medicine of hepatitis B, there is landmark contribution to medical field treating hepatitis B field.
Description
Technical field
The present invention relates to treating hepatitis B drug field, more particularly to a kind of pharmaceutical composition for treating hepatitis B.
Background technology
Virus B hepatitis is a kind of worldwide disease as caused by hepatitis type B virus (HBV), developing country's hair
Sick rate is high, and according to statistics, whole world Chronic asymptomatic carrier (HBsAg carrier) is more than 2.8 hundred million, and China accounts for 9300
Ten thousand, it is most asymptomatic, wherein 1/3 there is the clinical manifestation of hepatic lesion.The characteristics of there are hepatitis B patient 30,000,000, hepatitis B in current China
Relatively delay for onset, it is more typical with Subclinical and chronic type.The easy chronicity of non-icteric type HBsAg lasting masculin persons, this disease is main
By blood, mother and baby and property contact are propagated.The application of hepatitis B vaccine is prevention and the essential measure for controlling hepatitis B.
The research method of the current therapeutic type hepatitis B vaccine of China, Fudan University and Beijing Biological Product Inst.'s R ＆ D Cooperation
Hepatitis B antigen-antibody complex vaccine " second gram " be one of them.The vaccine is to exempt from HBsAg with high-titer hepatitis B
Epidemic disease globulin is configured to antigen-antibody complex by a certain percentage, for the treatment of chronic hepatitis B, belongs to protein vaccine.Should
Project is heard beautiful plum academician by Fudan University and headed the list of signers, and system the most is studied at home and is goed deep into, nearly 20 years so far, positive at present to carry out
III clinical trial phases.
The therapeutic hepatitis B vaccine developed jointly by Third Military Medical University and Chongqing beer company is set based on molecular epitope
Principle is counted, by imitating the polypeptide biological products that some peptide chains of hepatitis B antigen are synthesized, antibody is produced with inducing cell, belongs to polypeptide
Vaccine.The project is headed the list of signers by Third Military Medical University professor Wu Yuzhang, and II clinical trial phases are also carried out at present.
Guangzhou air hospital Zhang Yijun teaches the therapeutic hepatitis B vaccine and Chen Guang with the safe biological joint study in Shenzhen
The therapeutic DNA vaccine of the Collaboration on Scientific Research group research of oolemma neck, which gets the Green Light, carries out II phase clinical researches.
But in existing technology, it is not a kind of to be produced with the medicine of permanently effective healing hepatitis B, also just because of this,
The people that the current whole world there are about 10 is just perplexed by hepatitis B, and long-term prescription can not fully recover, the body to patient
Health, economic and family all brings the loss that can not be estimated.
The content of the invention
To solve the problem of above-mentioned prior art is present, it is an object of the invention to provide a kind of medicine group for treating hepatitis B
Compound, pharmaceutical composition convenient sources of the invention, therapeutic effect is notable, and therapeutic process is easily operated, and is treating hepatitis B neck
Domain is epoch-making to create.With huge medical value and economic value.
To reach above-mentioned purpose, the technical scheme is that：
A kind of pharmaceutical composition for treating hepatitis B, the pharmaceutical composition includes, first stage medication, second stage medication and
Phase III medication ... N stage medications, wherein, first stage medication is：Prevention hepatitis B vaccine, haptens A and auxiliary agent；
Second stage medication is prevention hepatitis B vaccine, haptens B and auxiliary agent；Phase III medication is prevention hepatitis B vaccine, partly resisted
Former C and auxiliary agent ... N stage medications are anti-use hepatitis B vaccine, haptens N and auxiliary agent, make the prevention hepatitis B epidemic disease in each stage
Seedling after corresponding different hapten conjugations from stimulating body persistently to produce antibody.
Further, the hepatitis B vaccine is Hepatitis B Vaccine Prepared From Yeast Recombinanted or recombinant C HO hepatitis B vaccines.
Further, in the pharmaceutical composition, haptens A, haptens B, haptens C... haptens N contain in molecule
Have carboxyl or can carboxylation haptens, containing amino or reducible nitro haptens, haptens containing sulfydryl, hydroxyl it is half anti-
Former, ketone group containing or ketone group haptens, other haptens such as penicillin, biotin, digoxin, fluorescein.
Further, in the pharmaceutical composition, haptens A, haptens B, it is many that haptens C... haptens N is selected from BCG vaccine
Ribosomal ribonucleic acid, prodigiosin, typhoid bacillus lipopolysaccharides etc..
Further, each haptens in the medication stage, used is differed, and medication stage N is not less than 17 times.
Further, the auxiliary agent is poly IC.
Further, the prevention is 30mg with the consumption of hepatitis B vaccine, and haptens N consumption is respectively：Typhoid bacillus
Lipopolysaccharides 1ml, 50 units/2ml prodigiosin 2ml, BCG vaccine polysaccharide nucleic acid 0.5mg.
Further, haptens N and the 2ml poly IC by 30mg preventions hepatitis B vaccine and the consumption is in 10ml
Be sufficiently mixed in container, after preserving 24h under 4 DEG C of constant temperature, afterwards by first stage medication, second stage medication ... N ranks
Section medication, carries out intramuscular injection, each stage injection interval is not less than 28 days successively.
Further, it is necessary to reduce internal hepatitis B number using medicine before using pharmaceutical composition of the present invention
Amount.
Further, used medicine is Aldoforwe ester, and Time of Administration is one month.
The present invention drug mechanism be：Innovative utilization haptens of the invention is theoretical, for being produced to hepatitis B vaccine
The patient of raw tolerance, by hepatitis B vaccine as a haptens, makes it be combined with another conventional haptens, to be produced in patient's body
Raw reactionogenicity, so as to produce hbv antibody, but during actual therapeutic, finds just with same haptens, resists
Body is difficult to long lasting for because after body produces antibody to the haptens, the antibody of the haptens is directed in later stage body
The haptens can be neutralized, so that being returned to the shape of the only remaining hepatitis B vaccine that can not produce reactionogenicity in patient's body again
State, because patient is resistant to no longer persistently produce antibody to hepatitis B vaccine, therefore, the present invention program innovative use stage
Property, different haptens and hepatitis B vaccine drug combination, so as to stimulate body persistently to produce hbv antibody, fundamentally reach healing
The purpose of hepatitis B.
Relative to prior art, beneficial effects of the present invention are：
The present invention is theoretical according to haptens, is connected using different haptens with prevention with hepatitis B vaccine, makes patient in short-term
The interior antibody produced can be long lasting for so as to reach the purpose for thoroughly curing hepatitis B, pharmaceutical composition of the invention is originated
Convenient, therapeutic effect is notable, and therapeutic process is easily operated, and is the epoch-making creation in treating hepatitis B field.With huge doctor
Treat value and economic value.It is that can thoroughly cure the initiative medicine of hepatitis B, to medical field treating hepatitis B to patient's non-hazardous
Field has landmark contribution.According to clinical verification, this method therapeutic effect significantly, has no side effect.
Embodiment
The present invention program is described in further detail with reference to specific embodiment：
A kind of pharmaceutical composition for treating hepatitis B, the pharmaceutical composition includes, first stage medication, second stage medication and
Phase III medication ... N stage medications, wherein, first stage medication is：Prevention hepatitis B vaccine, haptens A and auxiliary agent；
Second stage medication is prevention hepatitis B vaccine, haptens B and auxiliary agent；Phase III medication is prevention hepatitis B vaccine, partly resisted
Former C and auxiliary agent ... N stage medications are anti-use hepatitis B vaccine, haptens N and auxiliary agent, make the prevention hepatitis B epidemic disease in each stage
Seedling after corresponding different hapten conjugations from stimulating body persistently to produce antibody.
Further, the hepatitis B vaccine is Hepatitis B Vaccine Prepared From Yeast Recombinanted or recombinant C HO hepatitis B vaccines.
Further, in the pharmaceutical composition, haptens A, haptens B, haptens C... haptens N contain in molecule
Have carboxyl or can carboxylation haptens, containing amino or reducible nitro haptens, haptens containing sulfydryl, hydroxyl it is half anti-
Former, ketone group containing or ketone group haptens, other haptens such as penicillin, biotin, digoxin, fluorescein.
Further, in the pharmaceutical composition, haptens A, haptens B, it is many that haptens C... haptens N is selected from BCG vaccine
Ribosomal ribonucleic acid, prodigiosin, typhoid bacillus lipopolysaccharides etc..
Further, each haptens in the medication stage, used is differed, and medication stage N is not less than 17 times.
Further, the auxiliary agent is poly IC.
Further, the prevention is 30mg with the consumption of hepatitis B vaccine, and haptens N consumption is respectively：Typhoid bacillus
Lipopolysaccharides 1ml, 50 units/2ml prodigiosin 2ml, BCG vaccine polysaccharide nucleic acid 0.5mg.
Further, haptens N and the 2ml poly IC by 30mg preventions hepatitis B vaccine and the consumption is in 10ml
Be sufficiently mixed in container, after preserving 24h under 4 DEG C of constant temperature, afterwards by first stage medication, second stage medication ... N ranks
Section medication, carries out intramuscular injection, each stage injection interval is not less than 28 days successively.
Further, it is necessary to reduce internal hepatitis B number using medicine before using pharmaceutical composition of the present invention
Amount.
Further, used medicine is Aldoforwe ester, and Time of Administration is one month.
The present invention drug mechanism be：Innovative utilization haptens of the invention is theoretical, for being produced to hepatitis B vaccine
The patient of raw tolerance, by hepatitis B vaccine as a haptens, makes it be combined with another conventional haptens, to be produced in patient's body
Raw reactionogenicity, so as to produce hbv antibody, but during actual therapeutic, finds just with same haptens, resists
Body is difficult to long lasting for because after body produces antibody to the haptens, the antibody of the haptens is directed in later stage body
The haptens can be neutralized, so that being returned to the shape of the only remaining hepatitis B vaccine that can not produce reactionogenicity in patient's body again
State, because patient is resistant to no longer persistently produce antibody to hepatitis B vaccine, therefore, the present invention program innovative use stage
Property, different haptens and hepatitis B vaccine drug combination, so as to stimulate body persistently to produce hbv antibody, fundamentally reach healing
The purpose of hepatitis B.
Test example 1：
Patient Lee X, man, 36 years old, hepatitis B great three positive 3 years, with nausea, low fever, liver ascites is invalid through multi-treatment, profit
With the inventive method, Aldoforwe ester is taken one month, it is the first stage, 30mg preventions hepatitis B vaccine and typhoid bacillus fat is more
Sugared 1ml and 2ml poly ICs are sufficiently mixed in 10ml containers, after preserving 24h under 4 DEG C of constant temperature, intramuscular injection is produced in vivo
Hbv antibody, after 28 days, row second stage medication, by 30mg preventions hepatitis B vaccine and 50 units/2ml prodigiosin 2ml and
2ml poly ICs are sufficiently mixed in 10ml containers, after preserving 24h under 4 DEG C of constant temperature, intramuscular injection, after 28 days, the rank of row the 3rd
Section medication, 30mg preventions hepatitis B vaccine and BCG vaccine polysaccharide nucleic acid 0.5mg and 2ml poly IC are fully mixed in 10ml containers
Close, after preserving 24h under 4 DEG C of constant temperature, intramuscular injection ... it is anti-using prevention hepatitis B vaccine and not of the same race half through 17 stages
Original coupling makes body continue to produce antibody symptom disappearance after 16 months, and anti-HbsAg is the positive, and five displays of check have been cured, arrived
06 months mesh the previous years did not recurred.
Test example 2
Guo patient XX, man, 43 years old, hepatitis B "small three positive", with nausea, low fever is invalid through multi-treatment, utilizes present invention side
Method, takes Aldoforwe ester one month, the first stage, by 30mg preventions hepatitis B vaccine and typhoid bacillus lipopolysaccharides 1ml and 2ml
Poly IC is sufficiently mixed in 10ml containers, after preserving 24h under 4 DEG C of constant temperature, intramuscular injection produces hbv antibody in vivo,
After 28 days, by 30mg preventions hepatitis B vaccine and 50 units/2ml prodigiosin 2ml and 2ml poly IC in 10ml containers fully
Mixing, after preserving 24h under 4 DEG C of constant temperature, intramuscular injection, through 17 stages using prevention hepatitis B vaccine and not homologous hapten
Coupling makes body continue to produce antibody symptom disappearance after 16 months, and anti-HbsAg is the positive, and five displays of check have been cured, to mesh
The first half did not recurred.
Test example 3：
Patient Zhao XX, female, 51 years old, hepatitis B great three positive 4 years, with nausea, low fever, hepatic sclerosis is tormented by slight illness for a long time,
Using the inventive method, Aldoforwe ester is taken one month, the first stage, by 30mg preventions hepatitis B vaccine and typhoid bacillus fat
Polysaccharide 1ml and 2ml poly IC are sufficiently mixed in 10ml containers, after preserving 24h under 4 DEG C of constant temperature, intramuscular injection, in vivo production
Raw hbv antibody, after 28 days, row second stage medication, by 30mg preventions hepatitis B vaccine and 50 units/2ml prodigiosin 2ml
And 2ml poly ICs are sufficiently mixed in 10ml containers, after preserving 24h under 4 DEG C of constant temperature, intramuscular injection, after 28 days, row the 3rd
Stage medication, by 30mg preventions hepatitis B vaccine and BCG vaccine polysaccharide nucleic acid 0.5mg and 2ml poly IC in 10ml containers fully
Mixing, after preserving 24h under 4 DEG C of constant temperature, intramuscular injection, through 20 stages using prevention hepatitis B vaccine and not homologous hapten
Coupling makes body continue to produce antibody symptom disappearance after 18 months, and anti-HbsAg is the positive, and five displays of check have been cured, to mesh
The first two years did not recurred for 03 months.
The foregoing is only a specific embodiment of the invention, but protection scope of the present invention is not limited thereto, any
The change or replacement expected without creative work, should all be included within the scope of the present invention.Therefore, it is of the invention
Protection domain should be determined by the scope of protection defined in the claims.
Claims (8)
1. a kind of pharmaceutical composition for treating hepatitis B, it is characterised in that the pharmaceutical composition includes, first stage medication, second
Stage medication and phase III medication are to N stage medications, and medication stage N is not less than 17 times, wherein, first stage medication is：
Prevention hepatitis B vaccine, haptens A and auxiliary agent；Second stage medication is prevention hepatitis B vaccine, haptens B and auxiliary agent；3rd
Stage medication is prevention hepatitis B vaccine, haptens C and auxiliary agent, is prevention hepatitis B vaccine, haptens N to N stage medications
And auxiliary agent, each haptens in the medication stage, used differs, and makes prevention hepatitis B vaccine and the stage in each stage
Hapten conjugation after so as to stimulating body persistently to produce antibody.
2. pharmaceutical composition according to claim 1, it is characterised in that the hepatitis B vaccine is Hepatitis B Vaccine Prepared From Yeast Recombinanted
Or recombinant C HO hepatitis B vaccines.
3. pharmaceutical composition according to claim 2, it is characterised in that in the pharmaceutical composition, haptens A, haptens
B, haptens C to haptens N in molecule containing carboxyl or can carboxylation haptens, anti-containing amino or reducible nitro half
Original, the haptens of the haptens of haptens containing sulfydryl, hydroxyl, ketone group containing.
4. pharmaceutical composition according to claim 3, it is characterised in that in the pharmaceutical composition, haptens A, haptens
B, haptens C are to haptens N selected from BCG vaccine polysaccharide nucleic acid, prodigiosin, typhoid bacillus lipopolysaccharides.
5. pharmaceutical composition according to claim 2, it is characterised in that the auxiliary agent is poly IC.
6. pharmaceutical composition according to claim 4, it is characterised in that the prevention is with the consumption of hepatitis B vaccine
30mg, haptens N consumption is respectively：Typhoid bacillus lipopolysaccharides 1ml, 50 units/2ml prodigiosin 2ml, BCG vaccine polysaccharide core
Sour 0.5mg.
7. the pharmaceutical composition according to any claim in claim 1-6, it is characterised in that using the medicine
, it is necessary to reduce internal hepatitis B quantity using medicine before composition.
8. pharmaceutical composition according to claim 7, it is characterised in that used medicine is Aldoforwe ester, is taken
Time is one month.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410453195.5A CN104208670B (en) | 2014-09-09 | 2014-09-09 | A kind of pharmaceutical composition for treating hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410453195.5A CN104208670B (en) | 2014-09-09 | 2014-09-09 | A kind of pharmaceutical composition for treating hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104208670A CN104208670A (en) | 2014-12-17 |
| CN104208670B true CN104208670B (en) | 2017-07-28 |
Family
ID=52090842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410453195.5A Active CN104208670B (en) | 2014-09-09 | 2014-09-09 | A kind of pharmaceutical composition for treating hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104208670B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300222A (en) * | 1998-02-12 | 2001-06-20 | 免疫合成物公司 | Strategically modified hepatitis b core proteins and their derivatives |
| CN101125202A (en) * | 2006-08-15 | 2008-02-20 | 马胜录 | Protein vaccine used for processing immune tolerant treatment to hepatitis B |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814285A (en) * | 2005-11-22 | 2006-08-09 | 广州市恺泰生物科技有限公司 | Vaccine composition for treating B-type hepatitis and preparing method |
| CN100389823C (en) * | 2005-12-29 | 2008-05-28 | 中国人民解放军第三军医大学第三附属医院 | Preparation method and application of hepatitis B vaccine |
| KR100900837B1 (en) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | Potent vaccine composition comprising lipopeptides and poly (I: C) as adjuvant |
-
2014
- 2014-09-09 CN CN201410453195.5A patent/CN104208670B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300222A (en) * | 1998-02-12 | 2001-06-20 | 免疫合成物公司 | Strategically modified hepatitis b core proteins and their derivatives |
| CN101125202A (en) * | 2006-08-15 | 2008-02-20 | 马胜录 | Protein vaccine used for processing immune tolerant treatment to hepatitis B |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104208670A (en) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ606765A (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| RU2015116264A (en) | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN PATIENTS WITH DIABETES | |
| CN104208670B (en) | A kind of pharmaceutical composition for treating hepatitis B | |
| Centers for Disease Control and Prevention (CDC | Updated recommendations for use of Haemophilus influenzae type b (Hib) vaccine: reinstatement of the booster dose at ages 12-15 months | |
| CN104000958A (en) | External application ointment for treating panaritium and preparing method of external application ointment | |
| Wang et al. | Expert consensus statement on Xiyanping Injection for respiratory system infectious diseases in clinical practice (adults) | |
| CN101152552A (en) | Traditional Chinese medicine for treating pernicious vomiting due to spleen-stomach deficiency | |
| CN102988977A (en) | Multivalent vaccines | |
| CN108524550B (en) | Preparation method of SEB toxoid vaccine aerosol lung delivery immune mouse model | |
| CN105056230A (en) | Application of beta-lapachone, and beta-lapachone containing compound adjuvant and vaccine | |
| CN1326567C (en) | Egg yolk antibody composition for preventing and treating atypical pneumonia and its preparation method | |
| Robinson et al. | COVID-19: Vaccine and antimicrobial resistance what are the global implications? | |
| LIU | Clinical study on acupuncture combined with medication in restoration of gastrointestinal functions for postoperative patients with gastric cancer | |
| CN102241758A (en) | Preparation method and medical application of cervical carcinoma associated trichina antigen antibody | |
| Lu et al. | Transcontinental translational medicine collaboration: a successful Sino-Cuban Joint B-to-B program | |
| Sarter et al. | Successful treatment of chronic viral hepatitis with high-dilution medicine | |
| Hussain et al. | The general situation of Covid-19 in Iraq | |
| Zhu et al. | Characterization of Intestinal Microbic and Metabolic Microenvironment Signatures of Inflammatory Bowel Disease. | |
| Yousong | An Overview of New Drugs Approved in the US, EU and Japan in March 2018 | |
| Lee et al. | A Multicenter, Open-Label, Controlled, Randomized Study Comparing 4 g Once Daily with 2 g Two Times Daily Prolonged-Release Mesalamine for Mild to Moderate active Ulcerative Colitis. | |
| Carmela | A single blinded randomized clinical trial on the effects of oxytocin discontinuation versus continuous oxytocin infusion during the active phase of labor | |
| CN103751777B (en) | Diammonium glycyrrhizinate adjuvant and the vaccine containing diammonium glycyrrhizinate adjuvant | |
| CN105687645A (en) | Traditional Chinese medicine for treating allergic dermatitis | |
| Zhang MingDi et al. | Observation of clinical efficacy of rabeprazole combined with kangfuxin solution in treatment of acute gastritis attack and gastric ulcer caused by acute alcoholic gastric injury. | |
| CN104666378A (en) | Traditional Chinese medicine preparation for treating poliomyelitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |